The safety assessment is based on all data from 1,203 patients in the ongoing Phase III placebo-controlled trials DUET-1 and DUET-2 in antiretroviral treatment-experienced HIV-1 infected adult patients, 599 of whom received INTELENCE (200 mg b. i. d.) (see section 5.1).